Home/Pipeline/Undisclosed CKD Program

Undisclosed CKD Program

Chronic Kidney Disease

Pre-clinicalActive

Key Facts

Indication

Chronic Kidney Disease

Phase

Pre-clinical

Status

Active

Company

Averoa

About Averoa

Averoa is a private, Paris-based biotech focused on the high-need nephrology sector, leveraging decades of industry experience from its founding team. The company is in a pre-revenue, early-stage development phase, building a pipeline to treat chronic kidney disease (CKD) and rare renal tubulopathies. With a leadership team that includes veterans from Advicenne and major pharma, Averoa combines deep clinical development expertise with a strategic regulatory vision to advance its programs.

View full company profile

Therapeutic Areas

Nephrology Metabolic Diseases

Other Chronic Kidney Disease Drugs

Drug	Company	Phase	Status
FT012	Certa Therapeutics	Preclinical	Active
Renadyl	Centaur Pharmaceuticals	Phase 2	Active
BASH-001	Bash Biotech	Preclinical	Active
XGal-3® Apheresis Column	Eliaz Therapeutics	Research	Active
Platform Application - CKD	MultiOmic Health	Discovery	Active